[Skip to Navigation]
February 1990

Tumor-Associated Antigen Immune Complexes: A Potential Marker of Recurrent Melanoma

Author Affiliations

From the Division of Surgical Oncology, John Wayne Cancer Clinic, Armand Hammer Laboratories, Jonsson Comprehensive Cancer Center, UCLA School of Medicine (Drs Wong, Gupta, and Morton, and Ms Xu); and the Surgical Service, Section of Surgical Oncology, Sepulveda (Calif) Veterans Administration Medical Center (Dr Wong). Dr Wong is a recipient of the Career Development Award from the American Cancer Society.

Arch Surg. 1990;125(2):187-191. doi:10.1001/archsurg.1990.01410140065011

• To determine the potential utility of antigen-specific immune complex analysis, we developed a competitive enzyme-linked immunosorbent assay utilizing polyclonal human antibody to detect tumor-associated antigen-specific immune complexes. Sera from 10 normal volunteers and 19 patients with recurrent melanoma were studied. Patients with recurrent melanoma had a mean ± SD percent inhibition of 27.6% ± 29.8% in contrast to normal individuals with a mean value of 8.4% ± 17.8%. A monoclonal antibody (MAb JSI) was developed following immunization with a partially purified antigen. Utilizing MAb JSI, we developed a "sandwich" enzyme-linked immunosorbent assay and studied sera from 45 normal volunteers and 44 patients with cancer with recurrent melanoma. Results were expressed as a percent maximum binding of a positive control. The mean ± SD percent maximum binding for normal subjects was 4.9% ± 7.7% in contrast to sera from patients with melanoma who had a mean of 38.3% ±33.3%. Serial analysis of four patients with melanoma with tumor-associated antigen-specific immune complexes demonstrated the presence of tumor-associated antigen-specific immune complexes up to 12 years prior to clinical recurrence.

(Arch Surg. 1990;125:187-191)